$15.76
-0.03-0.19%
al cierre: Aug 19, 5:00 PM EST
$15.00
-0.76-4.82%
After hour: 4:01 PM EST
Lyell Immunopharma (LYEL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.00 | $-2.45 | $-2.20 | $-2.71 |
| Actual | $-1.92 | $-1.10 | $-7.68 | $-2.13 |
| Surprise | +4.00% | +55.1% | -249.1% | +21.4% |
| Revenue | ||||
| Estimate | $4600 | $4400 | $20330 | — |
| Actual | $4000 | $2000 | $6000 | $15000 |
| Surprise | -13.0% | -54.5% | -70.5% | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.91 | $-1.69 | $-2.28 | $-2.45 |
| Revenue | ||||
| Consensus | $3290 | $2430 | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-1.92 | $-2.00 | 4.00 % |
| Q1 | May 6, 2026 | $-1.10 | $-2.45 | 55.1 % |
| Q4 | Mar 12, 2026 | $-7.68 | $-2.20 | -249.1 % |
| Q3 | Nov 12, 2025 | $-2.13 | $-2.71 | 21.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $4.00K | $4.60K | -13.0 % |
| Q1 | May 6, 2026 | $2.00K | $4.40K | -54.5 % |
| Q4 | Mar 12, 2026 | $6.00K | $20.33K | -70.5 % |
| Q3 | Nov 12, 2021 | $2.76M | $2.30M | 19.8 % |